Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
oral
|
| gptkbp:affects |
insulin sensitivity
hepatic glucose production |
| gptkbp:affiliatedWith |
gptkb:biguanides
|
| gptkbp:approvedBy |
1957 (France)
1995 (USA) |
| gptkbp:ATCCode |
A10BA02
|
| gptkbp:CASNumber |
657-24-9
|
| gptkbp:chemicalFormula |
C4H11N5
|
| gptkbp:compatibleWith |
type 1 diabetes
|
| gptkbp:contraindication |
renal impairment
severe liver disease |
| gptkbp:discoveredBy |
gptkb:James_Bell
gptkb:Emile_Werner |
| gptkbp:discoveredIn |
1922
|
| gptkbp:eliminatedIn |
renal excretion
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dimethylbiguanide
|
| gptkbp:listedOn |
gptkb:WHO_Model_List_of_Essential_Medicines
|
| gptkbp:meltingPoint |
223–226 °C
|
| gptkbp:molecularWeight |
129.164 g/mol
|
| gptkbp:otherName |
gptkb:Metformin
|
| gptkbp:PubChem_CID |
4091
DB00331 |
| gptkbp:sideEffect |
gastrointestinal upset
lactic acidosis |
| gptkbp:treatment |
gptkb:type_2_diabetes
|
| gptkbp:usedAs |
antidiabetic drug
|
| gptkbp:bfsParent |
gptkb:DB00787
gptkb:DB00773 gptkb:DB00705 |
| gptkbp:bfsLayer |
7
|